{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T00:23:11Z","timestamp":1794010991197,"version":"4.8.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1245\/s10434-025-18641-7","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T21:17:43Z","timestamp":1761859063000},"page":"1381-1390","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Is Surgery Necessary for Stage IVB Gastric Cancer Showing Clinical Complete Response to Chemotherapy or Systemic Cancer Therapy?"],"prefix":"10.1245","volume":"33","author":[{"given":"Takumi","family":"Habu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinpei","family":"Ushiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izuma","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Yura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsumasa","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kuwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Shitara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"issue":"3","key":"18641_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"9742","key":"18641_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"Y-J Bang","year":"2010","unstructured":"Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687\u201397.","journal-title":"Lancet"},{"issue":"8","key":"18641_CR3","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S1470-2045(20)30315-6","volume":"21","author":"Y-K Kang","year":"2020","unstructured":"Kang Y-K, Chin K, Chung HC, Kadowaki S, Oh SC, Nakayama N, et al. S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial. Lancet Oncol. 2020;21(8):1045\u201356.","journal-title":"Lancet Oncol"},{"issue":"10294","key":"18641_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340.","journal-title":"Lancet"},{"issue":"2","key":"18641_CR5","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(2):234\u201347.","journal-title":"Lancet Oncol"},{"issue":"7903","key":"18641_CR6","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41586-022-04508-4","volume":"603","author":"K Shitara","year":"2022","unstructured":"Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature. 2022;603(7903):942\u20138.","journal-title":"Nature"},{"issue":"11","key":"18641_CR7","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Yanez P, Bai Y, Ryu MH, Lee J, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(11):1181\u201395.","journal-title":"Lancet Oncol"},{"key":"18641_CR8","doi-asserted-by":"crossref","unstructured":"Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401(10389):1655\u201368.","DOI":"10.1016\/S0140-6736(23)00620-7"},{"key":"18641_CR9","doi-asserted-by":"crossref","unstructured":"Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med. 2023;29(8):2133\u201341.","DOI":"10.1038\/s41591-023-02465-7"},{"key":"18641_CR10","doi-asserted-by":"crossref","unstructured":"Choe HJ, Kim JW, Han SH, Lee JH, Ahn SH, Park DJ, et al. Conversion surgery in metastatic gastric cancer and cancer dormancy as a prognostic biomarker. Cancers (Basel). 2019;12(1).","DOI":"10.3390\/cancers12010086"},{"issue":"2","key":"18641_CR11","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s10120-015-0575-z","volume":"19","author":"K Yoshida","year":"2015","unstructured":"Yoshida K, Yamaguchi K, Okumura N, Tanahashi T, Kodera Y. Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer. 2015;19(2):329\u201338.","journal-title":"Gastric Cancer."},{"issue":"2","key":"18641_CR12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3892\/mco.2017.1128","volume":"6","author":"T Einama","year":"2017","unstructured":"Einama T, Abe H, Shichi S, Matsui H, Kanazawa R, Shibuya K, et al. Long-term survival and prognosis associated with conversion surgery in patients with metastatic gastric cancer. Mol Clin Oncol. 2017;6(2):163\u20136.","journal-title":"Mol Clin Oncol"},{"issue":"10","key":"18641_CR13","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s00595-017-1512-z","volume":"47","author":"H Mieno","year":"2017","unstructured":"Mieno H, Yamashita K, Hosoda K, Moriya H, Higuchi K, Azuma M, et al. Conversion surgery after combination chemotherapy of docetaxel, cisplatin and S-1 (DCS) for far-advanced gastric cancer. Surg Today. 2017;47(10):1249\u201358.","journal-title":"Surg Today"},{"issue":"2","key":"18641_CR14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s10120-011-0015-7","volume":"14","author":"KH Kim","year":"2011","unstructured":"Kim KH, Lee KW, Baek SK, Chang HJ, Kim YJ, Park DJ, et al. Survival benefit of gastrectomy \u00b1 metastasectomy in patients with metastatic gastric cancer receiving chemotherapy. Gastric Cancer. 2011;14(2):130\u20138.","journal-title":"Gastric Cancer"},{"issue":"11","key":"18641_CR15","doi-asserted-by":"publisher","first-page":"6473","DOI":"10.21873\/anticanres.13010","volume":"38","author":"M Fukuchi","year":"2018","unstructured":"Fukuchi M, Mochiki E, Ishiguro T, Kumagai Y, Ishibashi K, Ishida H. Prognostic significance of conversion surgery following first- or second-line chemotherapy for unresectable gastric cancer. Anticancer Res. 2018;38(11):6473\u20138.","journal-title":"Anticancer Res"},{"key":"18641_CR16","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.ijsu.2018.04.016","volume":"53","author":"P Morgagni","year":"2018","unstructured":"Morgagni P, Solaini L, Framarini M, Vittimberga G, Gardini A, Tringali D, et al. Conversion surgery for gastric cancer: a cohort study from a western center. Int J Surg. 2018;53:360\u20135.","journal-title":"Int J Surg."},{"key":"18641_CR17","doi-asserted-by":"crossref","unstructured":"Al-Batran SE, Goetze TO, Mueller DW, Vogel A, Winkler M, Lorenzen S, et al. The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO\/CAO-V\/CAOGI. BMC Cancer. 2017;17(1):893.","DOI":"10.1186\/s12885-017-3918-9"},{"key":"18641_CR18","doi-asserted-by":"crossref","unstructured":"Salah-Eddin Al-Batran SL, Riera J, Caca K, Mueller C, Stange DE, Zander T. Effect of chemotherapy\/targeted therapy alone vs. chemotherapy\/targeted therapy followed by radical surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction: The IKF-575\/RENAISSANCE phase III trial. In: Jonathan W. Friedberg M, eds. ASCO Annual Meeting II: Journal of Clinical Oncology; 2024.","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA4001"},{"issue":"9742","key":"18641_CR19","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687\u201397.","journal-title":"Lancet"},{"key":"18641_CR20","doi-asserted-by":"crossref","unstructured":"Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2021 (6th ed). Gastric Cancer. 2023;26(1):1\u201325.","DOI":"10.1007\/s10120-022-01331-8"},{"key":"18641_CR21","doi-asserted-by":"crossref","unstructured":"Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, et al. Gastric Cancer, Version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(2):167\u201392.","DOI":"10.6004\/jnccn.2022.0008"},{"issue":"9","key":"18641_CR22","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1016\/j.ejso.2017.03.001","volume":"43","author":"G Tomasello","year":"2017","unstructured":"Tomasello G, Petrelli F, Ghidini M, Pezzica E, Passalacqua R, Steccanella F, et al. Tumor regression grade and survival after neoadjuvant treatment in gastro-esophageal cancer: a meta-analysis of 17 published studies. Eur J Surg Oncol. 2017;43(9):1607\u201316.","journal-title":"Eur J Surg Oncol"},{"key":"18641_CR23","doi-asserted-by":"crossref","unstructured":"Araujo RO, Valadao M, Borges D, Linhares E, de Jesus JP, Ferreira CG, et al. Nonoperative management of rectal cancer after chemoradiation opposed to resection after complete clinical response. A comparative study. Eur J Surg Oncol. 2015;41(11):1456\u201363.","DOI":"10.1016\/j.ejso.2015.08.156"},{"key":"18641_CR24","doi-asserted-by":"crossref","unstructured":"Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U, Jr., Silva e Sousa AH, Jr., et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240(4):711\u20137; discussion 7\u20138.","DOI":"10.1097\/01.sla.0000141194.27992.32"},{"key":"18641_CR25","doi-asserted-by":"crossref","unstructured":"Martens MH, Maas M, Heijnen LA, Lambregts DM, Leijtens JW, Stassen LP, et al. Long-term outcome of an organ preservation program after neoadjuvant treatment for rectal cancer. J Natl Cancer Inst. 2016;108(12).","DOI":"10.1093\/jnci\/djw171"},{"issue":"2","key":"18641_CR26","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S1470-2045(15)00467-2","volume":"17","author":"AG Renehan","year":"2016","unstructured":"Renehan AG, Malcomson L, Emsley R, Gollins S, Maw A, Myint AS, et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol. 2016;17(2):174\u201383.","journal-title":"Lancet Oncol"},{"issue":"4","key":"18641_CR27","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5896","volume":"5","author":"JJ Smith","year":"2019","unstructured":"Smith JJ, Strombom P, Chow OS, Roxburgh CS, Lynn P, Eaton A, et al. Assessment of a Watch-and-wait strategy for rectal cancer in patients with a complete response after neoadjuvant therapy. JAMA Oncol. 2019;5(4):e185896.","journal-title":"JAMA Oncol"},{"issue":"7","key":"18641_CR28","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1016\/j.clnu.2019.10.021","volume":"39","author":"E Rinninella","year":"2020","unstructured":"Rinninella E, Cintoni M, Raoul P, Pozzo C, Strippoli A, Bria E, et al. Muscle mass, assessed at diagnosis by L3-CT scan as a prognostic marker of clinical outcomes in patients with gastric cancer: a systematic review and meta-analysis. Clin Nutr. 2020;39(7):2045\u201354.","journal-title":"Clin Nutr"},{"issue":"2","key":"18641_CR29","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s10120-011-0021-9","volume":"14","author":"S Abdiev","year":"2011","unstructured":"Abdiev S, Kodera Y, Fujiwara M, Koike M, Nakayama G, Ohashi N, et al. Nutritional recovery after open and laparoscopic gastrectomies. Gastric Cancer. 2011;14(2):144\u20139.","journal-title":"Gastric Cancer"},{"key":"18641_CR30","doi-asserted-by":"crossref","unstructured":"Okazaki U, Nakayama I, Sakamoto N, Kuwata T, Kawazoe A, Yoshida M, et al. Clinical implementation of simultaneous multiple biomarkers testing for\u00a0metastatic or recurrent gastroesophageal adenocarcinoma: a single-institutional experience. ESMO Gastrointest Oncol. 2024;5.","DOI":"10.1016\/j.esmogo.2024.100086"},{"key":"18641_CR31","doi-asserted-by":"crossref","unstructured":"Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 8th ed. Wiley Blackwell; 2017.","DOI":"10.1002\/9780471420194.tnmc26.pub3"},{"key":"18641_CR32","unstructured":"Japanese Gastric Cancer A. Japanese classification of gastric carcinoma. fifteenth ed. Tokyo: Kanehira Shuppan. 2017 (in Japanese)."},{"key":"18641_CR33","doi-asserted-by":"crossref","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","DOI":"10.1016\/j.ejca.2008.10.026"},{"issue":"2","key":"18641_CR34","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205\u201313.","journal-title":"Ann Surg"},{"issue":"3","key":"18641_CR35","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138.","journal-title":"Bone Marrow Transplant."},{"issue":"1","key":"18641_CR36","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1245\/s10434-013-3055-x","volume":"21","author":"T Yoshikawa","year":"2014","unstructured":"Yoshikawa T, Tanabe K, Nishikawa K, Ito Y, Matsui T, Kimura Y, et al. Induction of a pathological complete response by four courses of neoadjuvant chemotherapy for gastric cancer: early results of the randomized phase II COMPASS trial. Ann Surg Oncol. 2014;21(1):213\u20139.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"18641_CR37","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1470-2045(15)00553-7","volume":"17","author":"K Fujitani","year":"2016","unstructured":"Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17(3):309\u201318.","journal-title":"Lancet Oncol"},{"key":"18641_CR38","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00535","volume":"6","author":"H Bando","year":"2022","unstructured":"Bando H, Nakamura Y, Taniguchi H, Shiozawa M, Yasui H, Esaki T, et al. Effects of metastatic sites on circulating tumor dna in patients with metastatic colorectal cancer. JCO Precis Oncol. 2022;6:e2100535.","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"18641_CR39","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41591-022-02115-4","volume":"29","author":"D Kotani","year":"2023","unstructured":"Kotani D, Oki E, Nakamura Y, Yukami H, Mishima S, Bando H, et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat Med. 2023;29(1):127\u201334.","journal-title":"Nat Med"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18641-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18641-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18641-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:33:10Z","timestamp":1767573190000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18641-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["18641"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18641-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"5 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Nakayama reports receiving research funding from Astellas, Ono Pharmaceutical Co., Ltd., Merck Sharp & Dohme (MSD), Daiichi Sankyo, Boehringer Ingelheim, and Chugai Pharmaceutical Co., Ltd. and honoria from Astellas, Ono Pharmaceutical Co., Ltd., Bristol Myers Squibb, Merck Sharp & Dohme (MSD), Daiichi Sankyo, and Chugai Pharmaceutical Co., Ltd. T. Kuwata reports receiving consulting fees from Amgen, Astellas, Daiichi Sankyo, MSD, Roche Diagnostics, and honoraria from Agilent, Astellas, Bristol Myer Squibb, Chugai Pharm, Falco Biosystems, Guardant Health, GxD, MSD, Roche Diagnostics, and SRL. Kohei\u00a0Shitara\u00a0reports receiving personal fees for consulting and advisory roles from Bristol Myers Squibb, Takeda, Ono Pharmaceutical, Novartis, Daiichi Sankyo, Amgen, Boehringer Ingelheim, Merck Pharmaceutical, Astellas, Guardant Health Japan, Janssen, AstraZeneca, Zymeworks Biopharmaceuticals, ALX Oncology Inc., Bayer, GlaxoSmithKline K.K., HEALIOS K.K., and Moderna.Inc, and Arcus Biosciences Inc.; receiving honoraria from Bristol-Myers Squibb, Ono Pharmaceutical, Janssen, Eli Lilly, Astellas, and AstraZeneca; and receiving research funding (all to institution) from Astellas, Ono Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Chugai, Merck Pharmaceutical, Amgen, Eisai, PRA Health Sciences, Syneos Health, AstraZeneca, PPD-SNBL K.K. and TORAY.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}},{"value":"Comprehensive informed consent regarding the retrospective study was obtained from all patients prior to treatment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}